Cargando…
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality
Anti-angiogenic therapy has increased the progression-free survival of many cancer patients but has had little effect on overall survival, even in colon cancer (average 6–8 weeks) due to resistance. The current licensed targeted therapies all inhibit VEGF signalling (Table1). Many mechanisms of resi...
Autores principales: | McIntyre, Alan, Harris, Adrian L |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403040/ https://www.ncbi.nlm.nih.gov/pubmed/25700172 http://dx.doi.org/10.15252/emmm.201404271 |
Ejemplares similares
-
Targeting hypoxic cancer stem cells (CSCs) with Doxycycline: Implications for optimizing anti-angiogenic therapy
por: De Francesco, Ernestina Marianna, et al.
Publicado: (2017) -
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
por: Pisarsky, Laura, et al.
Publicado: (2016) -
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
por: Allen, Elizabeth, et al.
Publicado: (2016) -
Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
por: Comunanza, Valentina, et al.
Publicado: (2017) -
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)